Optimal Regimens and Clinical Breakpoint of Avilamycin Against \textit{Clostridium perfringens} in Swine Based on PK-PD Study

Anxiong Huang\textsuperscript{1,2†}, Xun Luo\textsuperscript{1,2†}, Zihui Xu\textsuperscript{1,2}, Lingli Huang\textsuperscript{1,2}, Xu Wang\textsuperscript{1,2}, Shuyu Xie\textsuperscript{1,2}, Yuanhu Pan\textsuperscript{1,2}, Shiwei Fang\textsuperscript{1,2}, Zhenli Liu\textsuperscript{1,2}, Zonghui Yuan\textsuperscript{1,2} and Haihong Hao\textsuperscript{1,2*}

\textsuperscript{1}National Reference Laboratory of Veterinary Drug Residues (HZAU) and MOA (Ministry of Agriculture) Key Laboratory for Detection of Veterinary Drug Residues, Wuhan, China, \textsuperscript{2}MOA Laboratory for Risk Assessment of Quality and Safety of Livestock and Poultry Products, Wuhan, China

\textit{Clostridium perfringens} causes significant morbidity and mortality in swine worldwide. Avilamycin showed no cross resistance and good activity for treatment of \textit{C. perfringens}. The aim of this study was to formulate optimal regimens of avilamycin treatment for \textit{C. perfringens} infection based on the clinical breakpoint (CBP). The wild-type cutoff value (COWT) was defined as 0.25 \(\mu\text{g/ml}\), which was developed based on the minimum inhibitory concentration (MIC) distributions of 120 \textit{C. perfringens} isolates and calculated using ECOFFinder. Pharmacokinetics–pharmacodynamics (PK-PD) of avilamycin in ileal content were analyzed based on the high-performance liquid chromatography method and WinNonlin software to set up the target of PK/PD index (AUC\textsubscript{0–24h}/MIC)\textsubscript{ex} based on sigmoid E\textsubscript{max} modeling. The PK parameters of AUC\textsubscript{0–24h}, C\textsubscript{max}, and T\textsubscript{max} in the intestinal tract were 428.62 ± 14.23 h \(\mu\text{g/mL}\), 146.30 ± 13.41 \(\mu\text{g/ml}\),, and 4 h, respectively. The target of (AUC\textsubscript{0–24h}/MIC)\textsubscript{ex} for bactericidal activity in intestinal content was 36.15 h. The PK-PD cutoff value (CO\textsubscript{PD}) was defined as 8 \(\mu\text{g/ml}\) and calculated by Monte Carlo simulation. The dose regimen designed from the PK-PD study was 5.2 mg/kg mixed feeding and administrated for the treatment of \textit{C. perfringens} infection. Five respective strains with different MICs were selected as the infection pathogens, and the clinical cutoff value was defined as 0.125 \(\mu\text{g/ml}\) based on the relationship between MIC and the possibility of cure (POC) following nonlinear regression analysis, CART, and “Window” approach. The CBP was set to be 0.25 \(\mu\text{g/ml}\) and selected by the integrated decision tree recommended by the Clinical Laboratory of Standard Institute. The formulation of the optimal regimens and CBP is good for clinical treatment and to control drug resistance.

Keywords: \textit{Clostridium perfringens}, avilamycin, optimal regimens, clinical breakpoint, PK-PD

1 INTRODUCTION

\textit{Clostridium perfringens} is a common cause of intestinal diseases in humans, animals, fish, and their environment. It has caused serious damage to the global economy in the last few years (Allaart et al., 2014; Nan et al., 2017; Yadav et al., 2017; Yan et al., 2017). \textit{C. perfringens} can be divided into five types, including A, B, C, D, and E types, based on the differences between its toxigenic genes and pathogenicity (Hatheway 1990). \textit{C. perfringens} diseases in pigs are generally caused by type A and
type C (Lee et al., 2014). Type A is often linked to diarrhea in suckling piglets with mild necrotizing enterocolitis (Springer et al., 2012); hemorrhagic necrotic enteritis is induced by type C in piglets aged 0–2 weeks (Waters et al., 2003; Nan, Hao et al., 2017).

Avilamycin is an orthosomycin family antibiotic derived from the fermentation products of Streptomyces viridochromogenes (Mertz et al., 1986; Saito-Shida et al., 2018), including the major active factor avilamycin A and 15 other small factors (JECFA, 2004). Avilamycin is one of the EU-approved antimicrobial agents in the feed industry and is currently only used in animals to control bacterial enteric infections and multidrug-resistant gram-positive bacteria (Ho et al., 2013; Lv et al., 2013; OIE, 2015). Avilamycin has a strong treatment efficacy against necrotic enteritis (Vissiennon et al., 2000; Paradis et al., 2016). It does not display cross-resistance with any other antimicrobial agents, suggesting that this type of antimicrobial agents may represent an avenue for the for development of new antimicrobial agents (Aarestrup et al., 2000; Weitnauer et al., 2001; Arenz et al., 2016; Krupkin et al., 2016). It can be placed at the frontline of drugs due to its low environmental toxicity, extensive metabolism in vivo, and reduced ecological hazards (Arenz, Juette et al., 2016; Krupkin, Wekselman et al., 2016).

In order to reduce the occurrence of drug resistance, a reasonable dosing regimen is necessary. Pharmacokinetics—pharmacodynamics (PK-PD) study are very important for developing a reasonable dosing regimen (Yoshii et al., 2016). Many PK-PD studies mainly focus on the analysis of PK data in the plasma, because the data in the plasma is relatively stable and easy to obtain, but the Clinical Laboratory of Standard Institute (CLSI) also mentions that when conditions permit, the PK of target tissues can also be used (CLSI 2007a). For infections of C. perfringens, the drug concentration in the ileal contents (an unformed stool sample taken from the ileum) should be used. Compared with disease animal models, healthy animal models have better stability and reproducibility, which is even more important (CLSI 2007a).

The clinical breakpoint (CBP) is of great significance to antimicrobial susceptibility testing and monitoring of resistance (OIE 2016; Toutain et al., 2017; Lei et al., 2018). The determination of interpretive CBPs needs a comprehensive analysis of relevant information, including wild-type cutoff value (CO\textsubscript{WT})/epidemiological cutoff value, PK-PD cutoff value (CO\textsubscript{PD}), and clinical cutoff value (CO\textsubscript{CL}). The CO\textsubscript{WT} needs large numbers of in vitro minimum inhibitory concentrations (MICs) or zone diameter tests (Turnidge et al., 2007), and it allows the detection of resistance as a biological phenomenon (Toutain, Bousquet-Mélou et al., 2017). The CO\textsubscript{PD} is the relationship between drug concentrations and microbial PK parameters ex vivo (Kahlmeter et al., 2003; CLSI 2007a). The CO\textsubscript{CL} is the clinical outcomes with MIC from prospective clinical studies (Ambler et al., 2008). However, the clinical data is not easy to achieve from current studies; the CO\textsubscript{WT} could be used to separate susceptible isolates from isolates with resistance when there is a lack of clinical data (Espinel-Ingroff et al., 2011; Peng et al., 2016). But the CO\textsubscript{WT} cannot represent the CO\textsubscript{PD} and clinical efficacy (Barbour et al., 2010). When the three cutoff values are established, the decision tree from CLSI is applied for establishing the CBPs (CLSI, 2007a).

The purpose of the current study is to formulate the optimal regimens of avilamycin treatment for C. perfringens infection based on the CBP, and the CBP has been based on the CO\textsubscript{WT}, CO\textsubscript{PD}, and CO\textsubscript{CL} of avilamycin against C. perfringens.

## 2 MATERIALS AND METHODS

### 2.1 Chemicals and Reagents

Avilamycin premix (10%) was obtained from Eli Lilly, United States. Avilamycin (90%) was separated at the Institute of Veterinary Pharmaceuticals (Wuhan, China) and was confirmed by high-performance liquid chromatography (HPLC) and liquid chromatograph-mass spectrometer/Ion trap/Time of flight. All chemicals used in this experiment were of analytical or higher grade.

### 2.2 Bacterial Isolates

The clinical C. perfringens isolates were isolated from anal swab samples from piglets with or without diarrhea from large swine farms in the Henan, Hubei, Jiangxi, Liaoning, and Hunan Provinces of China. 120 positive stains were identified based on multiplex polymerase chain reaction. All bacteria were aerobic cultured on tryptose sulfate cycloserine agar bases containing 5% D-cycloserine. The control strain was Bacteroides fragilis ATCC 25285.

### 2.3 Animals

About 74 weaned, castrated, crossbred (Duroc × Large White × Landrace) pigs (15 ± 2 kg) were purchased from the Huazhong Agricultural University’s pig farm (Wuhan, China), details of which are as shown in Table 1. Two pigs were used to establish the HPLC method for the detection of avilamycin. Six pigs were used to conduct PK-PD experiments. The other pigs were used for the clinical trials. The pigs were acclimatized for 7 days before the experiment. All the animal experiments were approved by the Animal Ethics Committee of Huazhong Agricultural University (HZAUSW-2015-012) and the Animal Care Center, Hubei Science and Technology Agency, in China (SYXX 2013-0044). All efforts were taken to reduce the pain and adverse effects on the animals.

### 2.4 Determination of Wild-Type Cutoff Value for Avilamycin Against C. perfringens

We used the agar dilution method proposed by CLSI M11-A7, and the interpretation of the results was based on the graphical demonstrations in the CLSI documents (CLSI 2007b).

The CO\textsubscript{WT} was calculated following the method described by Turnidge et al. (2010), defined as the highest MIC for the wild-type comprising at least 95% of each MIC distribution, according to the CLSI guidelines (Pfaller et al., 2010; Pfaller et al., 2011). Ismail et al. (2018) developed the ECOFFinder program based on this principle, which brought the MIC.
distributions into the software, automatically fitted, and obtained CO_{WT}.

### 2.5 Determination of Pharmacokinetics–Pharmacodynamics Cutoff Value for Avilamycin Against C. perfringens

#### 2.5.1 In Vitro Pharmacodynamics of Avilamycin Against C. perfringens HS42

The strain HS42 near the CO_{WT} using a strong pathogenic test, by mouse virulence test, was chosen to determine the PK-PD study. The MIC of C. perfringens HS42 in the fluid thioglycollate medium (FT) and ileal contents was determined according to the broth dilution method recommended by CLSI M11-A7. By detecting the colony-forming unit (CFU) at different time points (0, 1, 2, 4, 6, 8, 12, and 24 h) under different MIC concentrations, we drew the in vitro time-kill curve.

#### 2.5.2 High-Performance Liquid Chromatography to Determine Avilamycin Concentration

An Agilent SB-Aq, 250 × 4.6 mm (i.d.), 5-μm column was used for HPLC, which was performed with a 290 nm detection wavelength at 30°C. The mobile phase consisted of 10 nmol/L ammonium acetate (phase A) and acetonitrile (phase B). The plasma was extracted with acetonitrile twice. The ileal content was extracted with acetone twice, and 10% NaCl solution was added with methylene chloride to the extraction. The solution was dried at 50°C under nitrogen. After drying, chloroform was added to dissolve the residue. The silica gel column (Waters, USA) was activated with methanol and chloroform. The dissolving solution was passed through the column to clean, the mixture of chloroform: acetone (4:1) was used to wash, and eluted with a mixture of chloroform: acetone (3:7). The mixture was vortexed and analyzed by liquid chromatography (Sunderland et al., 2004).

The avilamycin standard solution has good linearity in the range of 0.1–20 μg/ml ($R^2 = 0.9997$). In the plasma, the detection limit of determination (LOD) was 0.05 μg/ml and the limit of quantitation (LOQ) was 0.1 μg/ml. In the ileal content, the detection LOD was 0.08 μg/ml and the LOQ was 0.1 μg/ml.

#### 2.5.3 Sampling Procedures

A T-shape ileal cannula was installed in the ileum to get the ileal content. Pigs were allowed to recover fully in separate metabolism crates for about 2 weeks and were provided supplemental heat using infrared heating lamps. Before the experiment, food was withheld from the pigs for 36 h and water for 12 h. All the pigs were given 4 mg/kg b.w. of avilamycin by oral administration. At different time points (0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 h), the plasma was collected from the anterior cava, and the ileal content was collected into tubes from the T-shape ileal cannula at the same time. The samples were divided into two aliquots on ice and stored at −20°C for subsequent PK-PD studies.

#### 2.5.4 Ex Vivo Pharmacodynamics of Avilamycin Against C. perfringens HS42

The ex vivo time-kill curves were determined using the ileal content samples obtained from the pigs at different time points after oral administration of 4 mg/kg b.w. avilamycin.

#### 2.5.5 Pharmacokinetics–Pharmacodynamics Integration Analysis

The concentration–time data for avilamycin were analyzed for individual pigs by non-compartmental analysis (WinNonlin; TABLE 1 | Experimental grouping of pigs used in the study.

| Experiment         | Quantity | Use                      | Strains        | MIC (μg/ml) |
|--------------------|----------|--------------------------|----------------|------------|
| PK-PD study        | 2        | HPLC                     | —              | —          |
|                    | 6        | PK study                 | —              | —          |
| Clinical treatment | 6        | Blank                    | HG4            | 0.015      |
|                    | 6        | Treatment after infection| HN10           | 0.06       |
|                    | 6        |                           | HS42           | 0.25       |
|                    | 6        |                           | HS72           | 2          |
|                    | 6        |                           | HS101          | 8          |
|                    | 6        | No treatment after infection| HG4            | 0.015      |
|                    | 6        |                           | HN10           | 0.06       |
|                    | 6        |                           | HS42           | 0.25       |
|                    | 6        |                           | HS72           | 2          |
|                    | 6        |                           | HS101          | 8          |

MIC, minimum inhibitory concentration; PK, pharmacokinetics; PD, pharmacodynamics; HPLC, high-performance liquid chromatography.

FIGURE 1 | The minimum inhibitory concentration (MIC) distribution of avilamycin against 120 strains of Clostridium perfringens and nonlinear regression.
Pharsight Corporation, Mountain View, CA, United States) using the statistical moment approach. The inhibitory sigmoid $E_{\text{max}}$ model was used to determine the PD target under different efficiencies $[E = 0, -3, \text{and} -4 \text{ (bacteriostasis, bactericidal, and eradication, respectively)}]$. The model equation is as follows:

$$E = E_0 - \frac{PD_{\text{max}} \cdot C^N}{CN + EC_{50}^N}$$

where $E$ is the summary of PD endpoint and $E_0$ is the effect representing the value of the PD endpoint without drug treatment (i.e., the value of the summary endpoint when the PK-PD index is 0). $EC_{50}$ represents $(AUC_{0-24h}/MIC)_{\text{ex}}$ which produces 50% of the maximum antibacterial effect ($PD_{\text{max}}$). $C$ represents the $(AUC_{0-24h}/MIC)_{\text{ex}}$ ratio, $N$ represents the Hill coefficient, and $PD_{\text{max}}$ is the maximum effect (in relation to $E_0$) indicated by the plateau where increased exposures result in no further kill.

### 2.5.6 Monte Carlo Simulation and Pharmacokinetics–Pharmacodynamics Cutoff Value Analysis

Crystal Ball v7.2.2 was used to perform Monte Carlo simulation. The distribution of PK parameter $AUC_{0-24h}$ was assumed to be log-normal. A total of 10,000 subjects were simulated (Andes et al., 2004). The bactericidal effect was selected as a PD target to calculate the probability of target attainment (PTA). The $CO_{\text{PD}}$ was defined as the MIC at which the PTA was $\geq 90\%$.

### 2.6 Doses Estimation

Assuming PK linearity, the predicted daily doses were calculated by the dose equation (Toutain et al., 2002) as follows:

$$\text{Dose} = \frac{(AUC_{0-24h}/MIC)_{\text{ex}} \times MIC}{fu} \times \frac{CL}{F}$$

$CL/F$ represents the clearance scaled by bioavailability in ileal content, $(AUC_{0-24h}/MIC)_{\text{ex}}$ is the targeted endpoint for optimal efficacy in 24 h, $MIC$ is the target pathogen, and $fu$ is the proportion of free drugs in ileal content calculated by equilibrium dialysis.

The balance dialysis method was used to measure the binding rate of avilamycin to the contents of the porcine ileum, and the binding rate was converted into the free drug ratio. The dialysis bag containing blank ileal contents was suspended in dialysate with different drug concentrations and placed at 4°C for dialysis until equilibrium was reached. After the end of dialysis, the samples were taken from inside and outside of the dialysis bag and the drug concentration was determined. The binding rate was calculated based on the concentration. The binding rate $= (D_t - D_i)/D_t \times 100\%$, where $D_t$ is the drug concentration in the dialysis bag and $D_i$ is the liquid drug concentration outside the dialysis bag.

According to the formula of mixed feeding: $\text{Dose} = d \times t/W$ to decide the group dosage. Where $d$ is the oral dose (mg/kg b.w.), $W$ is the feed intake per 1 kg body weight of pigs for per 24 h, $t$ is the number of oral administration of drugs within 24 h. $W$ was not the same considering the difference in individual animals. For the piglets, the daily intake (24 h) accounts for 4–6% of their body weight (an average of 5%), i.e., 50 g per day per 1 kg of body weight.

The calculated dose, PK parameters, and PD parameters were brought into the Mlxplore software to simulate and predict the growth of bacteria under three doses (preventive dose, therapeutic dose, and eradication dose) and different administration intervals to obtain the best dosing schedule and dosing interval.

### 2.7 Determination of Clinical Cutoff Value for Avilamycin Against C. perfringens

#### 2.7.1 Clinical Efficacy by Different Minimum Inhibitory Concentrations

About 66 experimental piglets (15 ± 2 kg) were divided into 11 groups. Each group had six pigs. The type A C. perfringens, HG4 (0.015 μg/ml), HN10 (0.06 μg/ml), HS42 (0.25 μg/ml), HS72 (2 μg/ml), and HH101 (8 μg/ml) strains, which have β2 toxin and were chosen by the mouse virulence test, were used to conduct the clinical infected experiment. One group was the blank control group. Five groups were infected with five strains as the negative control groups. Five groups challenged with the five strains were the experimental groups. The negative control groups were infected without administration, the experimental groups were infected by administration, and the administration dose and interval were performed in accordance with the therapeutic administration dose established by the PK-PD study.

#### 2.7.2 Statistical Analysis

Three analytical methods were used, including "Window" approach, CART, and nonlinear regression analysis, to define the relationship between MIC and possibility of cure (POC) and determine the $CO_{\text{CL}}$.

The “Window” approach was calculated by CAR and MaxDiff, the cutoff value was between the CAR and MaxDiff when using the “Window” methods (Turnidge et al., 2017). CART was directly simulated by the Salford Predictive Modeler software; the MICs were used as a predictor and the clinical treatment outcomes were the target variable. The NRA was simulated by SPSS software; Log$_2$MICs were the independent variable and the POCs were the dependent variable.
2.8 Established Clinical Breakpoint
Three cutoff values were analyzed comprehensively using the decision tree proposed by CLSI document M37-A3 to decide the CBP (CLSI 2007a). When $C_{\text{WT}} = C_{\text{CL}}$, CBP is $C_{\text{WT}}$ and $C_{\text{CL}}$; when $C_{\text{WT}} > C_{\text{CL}}$, if $C_{\text{PD}}$ is the smallest, CBP is $C_{\text{CL}}$, otherwise CBP is $C_{\text{WT}}$; when $C_{\text{WT}} < C_{\text{CL}}$, if $C_{\text{PD}}$ is the smallest, CBP is $C_{\text{WT}}$, otherwise CBP is $C_{\text{CL}}$.

3 RESULTS

3.1 Wild-Type Cutoff Value for Avilamycin Against C. perfringens
The MIC distributions of avilamycin against the 120 clinical strains with diarrhea of C. perfringens type A is shown in Figure 1. The MIC values ranged from 0.015 to 256 μg/ml. The corresponding MIC<sub>50</sub> and MIC<sub>90</sub> were 0.06 and 128 μg/ml, respectively, suggesting that avilamycin displayed a potent antibacterial effect against anaerobic C. perfringens. The MIC distributions were brought into the ECOFFinder software, the cumulative distributions were calculated, and the cumulative distributions were fitted with nonlinear regression, the optimal fitting range was MIC ≤8 μg/ml. The calculated parameter values are shown in Table 2. The upper limit of the MIC distributions of C. perfringens in the 95% confidence interval was 0.25 μg/ml, defined as the $C_{\text{WT}}$.

3.2 Pharmacokinetics–Pharmacodynamics Cutoff Value for Avilamycin Against C. perfringens
3.2.1 Pharmacodynamics Study of C. perfringens HS42 In Vitro and Ex Vivo
The MIC of HS42 was 0.25 μg/ml both in FT and ileal content, which indicated that the ex vivo antibacterial activity of avilamycin was the same as that in vitro. In vitro and ex vivo time-kill curves of the varying concentrations of avilamycin against HS42 are shown in Figure 2. For in vitro time-kill curves (Figure 2A), avilamycin can exert better bactericidal effect (≥2 MIC); all bacterium were eradicated without recovery growth and the bactericidal effect was enhanced with the increase of drug concentrations. According to ex vivo time-kill curves (Figure 2B), the ileal content concentrations from 4 to 24 h could eradicate bacterium completely. The curves were characteristically typical for concentration-dependent antibiotic activity both in vitro and ex vivo. The PK-PD index (AUC<sub>0–24h</sub>/MIC)<sub>ex</sub> was selected to perform Monte Carlo simulation.
The concentrations of avilamycin in the plasma and ileal content were greatly different. The drug concentrations in the plasma were below the LOD, indicating that the amount of avilamycin absorbed into the blood is very small, which is suitable for the treatment of gastrointestinal diseases. The drug concentrations in the ileal content are shown in Figure 3. The integrated PK parameters derived from the non-compartmental analysis of ileal content for avilamycin after oral administration at a dose of 4 mg/kg b.w. are shown in Table 3. The AUC$_{0-24h}$ was 428.62 ± 14.23 μg/mL, $C_{\text{max}}$ was 146.30 ± 13.41 μg/mL, and $T_{\text{max}}$ was 4 h. The PK study results showed that the concentration of avilamycin in the digestive tract after oral administration was higher than in the plasma, but it was released and eliminated faster in the ileal contents.

The ileal content samples of 0, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h after the oral administration were used to determine the ex vivo antibacterial activity of avilamycin against HS42. Table 4 shows the ex vivo concentrations and antibacterial effect obtained from the killing curves. The results showed that the PK-PD index (AUC$_{0-24h}$/MIC)$_{\text{ex}}$ reached higher ranges in maintaining antimicrobial efficacy. The relationship between the antimicrobial efficacy and ex vivo (AUC$_{0-24h}$/MIC)$_{\text{ex}}$ ratios was simulated by the inhibitory Sigmoid $E_{\text{max}}$ equation, and the result is shown in Table 5. The values of (AUC$_{0-24h}$/MIC)$_{\text{ex}}$ at E = 0, –3, and –4 (bacteriostasis, bactericidal, and eradication) were 21.60, 36.15, and 53.24, respectively.

3.2.3 Monte Carlo Simulation and Pharmacokinetics–Pharmacodynamics Cutoff Value Determination

Based on AUC$_{0-24h}$ data of 428.62 h μg/mL and standard deviation of 14.23, Monte Carlo simulation was performed using Crystal Ball 7 software and AUC$_{0-24h}$ of 10,000 pigs were generated by simulation. The PK-PD target (AUC$_{0-24h}$/MIC)$_{\text{ex}}$ for Monte Carlo simulation was 21.60, 36.15, and 53.24 h which attained inhibition, sterilization, and eradication effect.

The PTA of avilamycin against C. perfringens under different antibacterial target was calculated based on the computation. For bacteriostatic action (E = 0), the PTA was 100% when the MIC was 8 μg/mL, while it was 0% when the MIC was 32 μg/mL. For bactericidal action (E = –3), the PTA ≥ 90% could be obtained for isolates with 8 ≤ MIC < 16 μg/mL. For bacterial eradication action (E = –4), the PTA was calculated to be 56.59% at the MIC value of 8 μg/mL, but 100% at the MIC value of 4 μg/mL. The PTA was dependent on the MICs and PK-PD target. The larger the target values, the smaller the MIC required to achieve 90% compliance rate (Figure 4).

In this study, the PK-PD target of 36.15 h, which attained bactericidal activity when E = –3, was selected to determine the CO$_{\text{PD}}$. Therefore, the CO$_{\text{PD}}$ of avilamycin against swine C. perfringens was defined as MIC of 8 μg/mL, representing the bactericidal effects.

3.3 Dose Regimen

The binding rate of avilamycin in the ileal contents of pigs was 0.35, measured by the equilibrium dialysis method, and the free drug ratio (fu) of avilamycin in the ileal contents of pigs was 0.65. The doses required to achieve different antibacterial effects of avilamycin could be calculated by substituting the PK-PD index values into the dose equation. The preventive doses, therapeutic doses, and eradication doses of avilamycin mixed feeding were calculated to be 3.6, 5.2, and 8.8 mg/kg, respectively. The corresponding calculated preventive doses, therapeutic doses, and eradication doses were 0.09, 0.13, and
0.22 mg/kg, respectively. MlxPlore software was used to predict *C. perfringens* at different doses and dosing intervals (Figure 5). The results show that when daily doses are given at 12 h intervals, the expected effect can be achieved.

### 3.4 Clinical Cutoff Value for Avilamycin Against *C. perfringens*

The number of dead animals, recovered animals, and cured animals were counted during the treatment trial. Table 6 shows the data on...

---

**TABLE 4 | Ex vivo concentration, \((AUC_{0-24 h}/MIC)_{ex}\), and antibacterial effect obtained from the killing curves.**

| Time (h) | \(C_{ex}^a\) | \((AUC_{0-24 h}/MIC)_{ex}^b\) | Count 0 h (log10 CFU/mL)c | Count 24 h (log10 CFU/mL)d | \(E (\log10 \text{ CFU/mL})^e\) |
|----------|--------------|-------------------------------|---------------------------|-----------------------|-------------------|
| 0        | 0            | 0                             | 5.37                      | 7.91                  | 2.54              |
| 2        | 0.11         | 10.56                         | 5.37                      | 7.64                  | 2.27              |
| 3        | 0.37         | 35.52                         | 5.37                      | 2.45                  | −2.92             |
| 4        | 146.30       | 14,044.80                     | 5.37                      | 1                     | −4.37             |
| 5        | 108.32       | 10,398.72                     | 5.37                      | 1                     | −4.37             |
| 6        | 54.25        | 5208.00                       | 5.37                      | 1                     | −4.37             |
| 8        | 18.07        | 1734.72                       | 5.37                      | 1                     | −4.37             |
| 10       | 12.94        | 1242.24                       | 5.37                      | 1                     | −4.37             |
| 12       | 3.45         | 331.20                        | 5.37                      | 1                     | −4.37             |
| 24       | 0.99         | 95.04                         | 5.37                      | 1                     | −4.37             |
| 36       | 0.21         | 20.16                         | 5.37                      | 2.58                  | −2.79             |

*a Drug concentrations at different times.

*b Ex vivo PK-PD indexes at different times.

*c Initial bacterial colonies incubated with different drug concentrations.

*d Terminal bacterial colonies incubated with different drug concentrations after 24 h.

*e Difference of antibacterial logarithm of ileal content samples incubated with the drug (d − c).

**TABLE 5 | Ex vivo pharmacodynamic parameters of avilamycin against Clostridium perfringens.**

| Parameters | Units       | Values | SD   |
|------------|-------------|--------|------|
| \(E_0\)   | Log10 CFU/mL| 2.53   | 0.02 |
| EC\(_{50}\) | h           | 24.99  | 0.21 |
| PD\(_{max}\) | Log10 CFU/mL | 6.91  | 0.01 |
| Slope (N) | —           | 3.76   | 0.08 |
| \((AUC_{0-24 h}/MIC)_{ex}\) for bacteriostatic action \((E = 0)\) | h | 21.60 | — |
| \((AUC_{0-24 h}/MIC)_{ex}\) for bactericidal action \((E = -3)\) | h | 36.15 | — |
| \((AUC_{0-24 h}/MIC)_{ex}\) for bacterial eradication action \((E = -4)\) | h | 53.24 | — |

**FIGURE 4 | The probability of target attainment (%) of attaining \([AUC_{0-24 h}/\text{minimum inhibitory concentration (MIC)}]_{ex}\) ratio values by Monte Carlo simulation.**
the mortality rate, effective rate, and cure rate of each group. When the MIC was 0.06 μg/ml, the POC was 100%, and when the MIC was 0.25 μg/ml, the POC was 83.33%. Therefore, the range of COCL should be 0.06–0.25 μg/ml when the POC attained 90%.

Firstly, the CAR (AUCsucc/AUCtotal) and MaxDiff calculation results are shown in Table 7. CAR could not be set at the lowest MIC or the highest MIC. If the CAR was increased with the MIC, then the second smallest CAR should be chosen as the final CAR. Based on this principle, the parameters MaxDiff and CAR were 0.22 and 0.85, respectively. The selection window of COCL was 0.06–2 μg/ml.

Secondly, the NRA model with the highest coefficient (cubic) to simulate the corresponding model expression was $y = 83.771 - 3.542x - 4.24x^2 - 0.054x^3$ (R = 0.94). According to the simulation expression, when POC was 90%, the Log2MIC was −2.17, and the equivalent MIC was 0.22 μg/ml. Thus, the recommended COCL was 0.06–0.22 μg/ml.

Finally, the data of the clinical trial (POC and MIC distributions) were brought into the Salford Predictive Modeler software for CART analysis. A regression tree was obtained as shown in Figure 6. From the regression tree, it could be seen that when MIC ≤ 0.16 μg/ml, the POC was 100%. When the MIC > 0.16 μg/ml, the POC was 86.7%. When the POC equals to 90%, the MIC should be greater than 0.16 μg/ml but less than 0.25 μg/ml. Combined with the distributions, we chose the MIC nearing 0.22 and 0.16 μg/mL as the COCL. Thus, the COCL for avilamycin against C. perfringens was 0.125 μg/ml.

### 3.5 Established Clinical Breakpoint

To sum up, the COWT was 0.25 μg/ml, the COPD was 8 μg/ml, and the COCL was 0.125 μg/ml. These three cutoffs were brought into the decision tree developed by the CLSI and were consistent with COPD > COWT > COCL. Therefore, the CBP of avilamycin against C. perfringens was 0.25 μg/ml.

### TABLE 6 | Probability of curve (POC) of avilamycin against Clostridium perfringens at different MICs.

| Group          | Strains (MIC) | Numbers | Number of dead animals | Dead rate | Effective rate | POC  |
|---------------|---------------|---------|------------------------|-----------|---------------|------|
| Blank         | —             | 6       | 0                      | 0         | —             | —    |
| Negative control | 0.015 μg/ml  | 6       | 1                      | 16.67%    | —             | —    |
|               | 0.06 μg/ml    | 6       | 1                      | 16.67%    | —             | —    |
|               | 0.25 μg/ml    | 6       | 1                      | 16.67%    | —             | —    |
|               | 2 μg/ml       | 6       | 2                      | 33.33%    | —             | —    |
|               | 8 μg/ml       | 6       | 3                      | 50%       | —             | —    |
| Treatment group | 0.015 μg/ml  | 6       | 0                      | 0         | 100%          | 100% |
|               | 0.06 μg/ml    | 6       | 0                      | 0         | 100%          | 100% |
|               | 0.25 μg/ml    | 6       | 1                      | 16.67%    | 83.33%        | 83.33% |
|               | 2 μg/ml       | 6       | 1                      | 16.67%    | 83.33%        | 83.33% |
|               | 8 μg/ml       | 6       | 2                      | 33.33%    | 66.67%        | 50%  |

MIC, minimum inhibitory concentration.
4 DISCUSSION

*C. perfringens* is an environmental bacterium existing in the breeding industry and responsible for enteric disease with focal necrosis in the intestine. Also, it is a pathogen to public health through the food chain (Silva et al., 2009). Because of the antibacterial used for growth promotion or to prevent pathogenic effects of *C. perfringens*, extensive microorganism susceptibility researches have been conducted. Several studies showed that the *C. perfringens* antibiotic resistance was high to penicillin, bacitracin, tetracycline, and lincomycin (Akhi et al., 2015). But the oligosaccharide antimicrobial agent, avilamycin, has shown excellent activity against *C. perfringens*. The MICs of 30 *C. perfringens* isolates for avilamycin were tested in the local poultry industry, and the concentrations ranged from 4 to 512 μg/ml (Redondo et al., 2015).

The MICs of avilamycin for 50 *C. perfringens* type A strains isolated from 1- to 7-day-old piglets, with or without diarrhea, ranged from 1 to 256 μg/ml, and the MIC with the highest number of strains was concentrated in 4 μg/ml (Salvarani et al., 2012).

In this study, the MIC distributions of avilamycin against the 120 clinical strains of *C. perfringens* ranged from 0.015 to 256 μg/ml, which had a wide scope than former research. Fitting the reported MIC data with our MIC distributions together, we got the same conclusion that the COWT was 0.25 μg/ml. The low MIC value (0.015 μg/ml) might be explained by regional disparities due to avilamycin not being popularly used in China. Meanwhile, the MIC distributions present a double peak, and there were a small number of resistant bacterium; the resistance mechanism of *C. perfringens* to avilamycin should be the focus and taken into account when establishing the COWT in future studies (Zheng et al., 2017). The mode of action of avilamycin is not well elaborated. It has been suggested that avilamycin acts by binding to the 30S part of the ribosome to inhibit bacterial protein synthesis (Wolf et al., 1973). However, a recent study indicated that resistance to avilamycin is associated with variations in the ribosomal protein L16 and thereby probably interacts with the peptidyl transferase activity. Some research showed that avilamycin binds to the 50S subunit, resulting in decreased susceptibility to avilamycin in bacteria (Mcnicholas et al., 2000). We usually need to adopt certain statistical methods to define the COWT by the NRA (Hao et al., 2013; Smith et al., 2014). Conventionally, the MIC values were logarithmically transformed, and the cumulative distributions were subjected to regression simulation. The gradient was added to each fitting from the smallest distributed MIC to the most distributed MIC. The fit was kept between the optimal range between the actual values and estimated values, with a 95% confidence interval. Then the probability was predicted above the upper limit and below the lower limit, respectively, with the COWT as the upper limit of the wild-type distributions. In this experiment, the ECOFFinder program based on the NRA, was used to gradually replace and simplify the fitting process. We only needed to put the MIC distributions into the software to automatically fit and obtain COWT.

PK-PD explored the relationship between the PK parameters and bacterial inhibition or killing and even extended it to the clinical outcome (Drusano, 2004). Over the last 30 years, a clear understanding of PK-PD on the many classes of antimicrobial agents had been researched, including the β-lactams, aminoglycosides, quinolones, macrolides, lincosamides, tetracyclines, and glycopeptides (Ambrose et al., 2007; Turnidge and Paterson 2007). In this study, we used healthy animals to establish the PK-PD model because the PK data were

**TABLE 7** | Window of differing MaxDiff and CAR values.

| MIC    | Cure success | Numbers | %Success ≤ MIC | %Success > MIC | MaxDiff | AUC_Succ | AUC_Total | CAR |
|--------|--------------|---------|----------------|----------------|---------|----------|-----------|-----|
| 0.015  | 6            | 6       | 1              | 0.83           | 0.14    | 0.045    | 0.045     | 1   |
| 0.06   | 6            | 6       | 1              | 0.78           | 0.22    | 0.02     | 0.02      | 1   |
| 0.25   | 5            | 6       | 0.83           | 0.75           | 0.08    | 1.41     | 1.51      | 0.93|
| 2      | 5            | 6       | 0.83           | 0.67           | 0.16    | 10.55    | 12.38     | 0.85|
| 8      | 4            | 6       | 0.67           | 0.67           | 0       | 39.31    | 50.26     | 0.78|

MIC, minimum inhibitory concentration.
often generated in healthy representatives of the target species and the healthy animal model was more stable than the disease model, as well as showed better repeatability (CLSI 2007a). Furthermore, we suggest that the animal model can also be established in diseased animals at the same time and compared with healthy animal models if permitted.

The index T > MIC was used for time-dependent antibacterial agents, but the indexes AUC0–24h/MIC and Cmax/MIC were used for concentration-dependent antibacterial agents. The selected PK-PD index determined the PD parameter that best predicts efficacy in the animal model (Jr et al., 2007). The human medicine, evernimicin, which belonged to the same class as avilamycin, had been used to evaluate the bactericidal and sterilizing efficacies. Evernimicin exhibited a concentration-dependent killing kinetics, as the ratio AUC0–24h/MIC was the best index correlated with a reduction of bacterial count (Drusano et al., 2001). The bacteriostatic characteristic of avilamycin against C. perfringens indicated concentration dependence too. Hence, the PK-PD index (AUC0–24h/MIC) has been considered to calculate avilamycin ex vivo activity.

Most of the current studies on PK development have focused on the analysis of data in the plasma because these data are relatively stable and relatively easy to obtain. The concentrations of the drug at the target sites were generally estimated on the basis of the concentrations of the serum or plasma because the drug concentrations at the infection sites were largely correlated to the serum or plasma (Craig 1998; Ping et al., 2002). In our study, the drug concentrations in the blood might not accurately reflect the drug concentrations of the target tissue. For some digestive tract drugs, the T-shape ideal method had been used in swine for a more accurate PK study of the drugs in the digestive tract which could provide the target animals with maintaining a normal physiological state. Furthermore, researchers had shown that the measurement of free drug concentrations was more important than the total drug concentrations for evaluating the antimicrobial activity (Andes et al., 2002).

At present, the most common method for setting COCL was to collect a large number of clinical cases (Toutain et al., 2010; Lee et al., 2016), integrate the data, and finally use statistical analysis methods to obtain COCL. Because of the limited clinical treatment of C. perfringens in pigs caused by avilamycin, the clinically challenged test had proceeded under laboratory conditions. The therapeutic dose adopted PK-PD recommended dosages which were linked to PK-PD with clinical treatment effect. The COCL formula POC = 1/[1 + e-a+bf (MIC)] proposed by EUCAST had not been applied in practice at present (Toutain et al., 2017). COCL reflected the upper limit of the MIC values associated with a high likelihood of clinical success (when POC equals to 90%). Based on this principle, five different MICs nearing MIC50, MIC90, COWT, sensitive, and resistant strains were selected for conducting the clinical treatments. Three statistical analysis methods, including the “Window” approach, NRA, and CART analysis, were used to analyze the results of the clinical trials (Bhat et al., 2007; Cuesta et al., 2009; Cuesta et al., 2010; Turnidge and Martinez 2017), predicting the POC corresponding to the MIC distributions.

Comparing these three cutoff values, it was not difficult to find that the COPD was much higher than COWT and COCL. Because the dose used in the PK-PD study was the recommended dose, which was a uniform dose for piglet diarrhea. C. perfringens was sensitive to avilamycin, and the drug was widely distributed in the digestive tract, leading to high AUC values and COPD. Specially, when the COWT equaled COCL, the COPD did not influence the final CBP. When the COWT did not equal COCL, the COPD was used as a weighting factor, but the CBP would be established by the primary determinant COWT or COCL (CLSI 2007a). There was no clear methodology for establishing the CBP in veterinary medicine. In this study, we provided a train of thought and suggested that if there were obvious differences between COCL, COWT, and COPD, the number of clinical samples should be expanded, and there is a need for expert subcommittee member deliberation on the relative weighting of these three cutoffs.

5 CONCLUSION

The rational use of antibiotics is becoming more and more important in veterinary clinics, and the abuse of antibiotics is the main reason for the development of bacterial resistance. After establishing three cutoff values in this study, the CBP of avilamycin against C. perfringens in swine was set to be 0.25 μg/ml, which can easily and clearly distinguish drug-resistant bacteria. At the same time, the findings of this study established that the optimal dosage of avilamycin for the treatment of pigs with C. perfringens infection is 5.2 mg/kg mixed feeding, and if the daily doses are given at 12 h intervals, the expected effect can be achieved.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, and further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by the Animal Ethics Committee of Huazhong Agricultural University.

AUTHOR CONTRIBUTIONS

AH, XL, ZY, and HH conceived and designed the experiments. AH, XL, ZX, and SF performed the experiments. AH, XL, ZY, and SF analyzed the data. LH, XW, SX, YP, ZL, ZY, and HH contributed reagents or materials or analysis tools. AH, XL, and HH wrote the manuscript. All authors contributed to the article and approved the submitted version.
FUNDING

This work was funded by grants from the National Key Research and Development program (No. 2021YFD1800600/2016YFD0501302/2017YFD0501406), the National Natural Science Foundation of China (No. 32172914/31772791), and the Fundamental Research Funds for the Central Universities (No. 2662018JC001).

ACKNOWLEDGMENTS

The authors are very grateful to Jinhua Zhang from Jiangxi Agricultural University and to Wenjin Zhang and Changmin Hu from the College of Veterinary Medicine of Huazhong Agricultural University for their help and useful suggestions surrounding these experiments.

REFERENCES

Aarestrup, F. M., and Jensen, L. B. (2000). Presence of Variations in Ribosomal Protein L16 Corresponding to Susceptibility of Enterococci to Oligosaccharides (Avalamycin and Evernimicin). Antimicrob. Agents Chemother. 44 (12), 3425–3427. doi:10.1128/ AAC.44.12.3425-3427.2000

Akhi, M. T., Bidar Asl, S., Pirzadeh, T., Naghili, B., Veganeh, F., Memar, Y., et al. (2015). Antibiotic Sensitivity of clostridium Perfringens Isolated from Feces in Tabriz, iran. Jundishapur J. Microbiol. 8 (7), e20863. doi:10.5812/jjm.20863v2

Allaart, J. G., van Asten, A. J., Vernooy, J. C., and Gröne, A. (2014). Beta2 Toxin Is Not Involved in In Vitro Cell Cytotoxicity Caused by Human and Porcine Cpb2-Containing Clostridium perfringens. Vet. Microbiol. 171 (1-2), 132–138. doi:10.1016/j.vetmic.2014.03.020

Ambler, J., Rennie, R., Poupart, J., Koeth, L., Stass, H., Endermann, R., et al. (2008). Ambrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., et al. (2008). CLSI (2007b). “Established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST).” Antimicrob. Agents Chemother. 53 (7), 2949–2954. doi:10.1128/ AAC.00081-09

Drusano, G. L. (2004). Antimicrobial Pharmacodynamics: Critical Interactions of Drug and Drug. Nat. Rev. Microbiol. 2 (4), 289–300. doi:10.1038/nrmicro862

Drusano, G. L., Preston, S. L., Hardalo, C., Hare, R., Banfield, C., Andes, D., et al. (2001). Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint. Antimicrob. Agents Chemother. 45 (1), 13–22. doi:10.1128/AAC.45.1.13-22.2001

Eapen-Ingraff A., Fothergill, A., Fuller, J., Johnson, E., Pela e, T., and Turnidge, J. (2011). “Wild-Type MIC Distributions and Epidemiological Cutoff Values for Caspofungin and Aspergillus Spp. For the CLSI Broth Microdilution Method (M38-A2 Document).” Antimicrob. Agents Chemother. 55 (6), 2855–2859. doi:10.1128/AAC.01730-10

Hao, H., Pan, H., Ahmad, L., Cheng, G., Wang, Y., Dai, M., et al. (2013). Susceptibility Breakpoint for Enrofloxacin against Swine Salmonella Spp. J. Clin. Microbiol. 51 (9), 3070–3072. doi:10.1128/JCM.01106-13

Hatheway, C. L. (1990). Toxigenic Clostridia. Clin. Microbiol. Rev. 3 (1), 66–98. doi:10.1128/cmr.3.1.66

Ho, C., and Wong, Y. T. (2013). Determination of Avalamycin as Dichloroisoacetic Acid in Poultry and Porcine Muscles by Isotope Dilution Liquid Chromatography-Tandem Mass Spectrometry. Anal. Bioanal. Chem. 405 (26), 8633–8643. doi:10.1007/s00216-013-7262-x

Ismail, N. A., Omar, V. S., Joseph, L., Govender, N., Blows, L., Ismail, F., et al. (2018). Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EbioMedicine 28, 136–142. doi:10.1016/j.ebiom.2018.01.005

JECEA (2004). “Toxicological Evaluation of Certain Veterinary Drug Residues in Food. Italy: World Health Organization.”

Ir, R., and Ambrose, P. G. (2007). Antimicrobial Stewardship and the Role of Pharmacokinetics–pharmacodynamics in the Modern Antibiotic Era. Diagn. Microbiol. Infect. Dis. 57 (3-suppl-S), S77–S83. doi:10.1016/j.diagmicrobio.2006.12.012

Kahlmeter, G., Brown, D. F., Goldstein, W. F., Macgowan, A. P., Mouton, J. W., Osterlund, A., et al. (2003). European Harmonization of MIC Breakpoints for Antimicrobial Susceptibility Testing of Bacteria. J. Antimicrob. Chemother. 52 (2), 145–148. doi:10.1093/jac/dkg312

Krupkin, M., Welskeman, I., Matzov, D., Eyal, Z., Diskin Posner, Y., Rozenberg, H., et al. (2016). Avalamycin and Evernimicin Induce Structural Changes in rProteins uL16 and CTC that Enhance the Inhibition of A-Site tRNA Binding. Proc. Natl. Acad. Sci. U S A. 113, 7527–7532. doi:10.1073/pnas.1607901113

Barbour, A., Scaglione, F., and Derendorf, H. (2010). Class-dependent Relevance of Tissue Distribution in the Interpretation of Anti-infective Pharmacokinetic/pharmacodynamic Indices. Int. J. Antimicrob. Agents. 35 (5), 431–438. doi:10.1016/j.ijantimicag.2010.01.023

Bhat, S. V., Peleg, A. Y., Lodise, T. P., Shutt, K. A., Capitano, B., Potoski, B. A., et al. (2007). Failure of Current Cephalosporin Breakpoints to Predict Clinical Outcomes of Bacteremia Caused by Gram-Negative Organisms. Antimicrob. Agents Chemother. 51 (12), 4390–4395. doi:10.1128/AAC.01487-06

CLSI (2007a). “Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents: Approved Guideline,” in CLSI Document M37-A3. Clinical and Laboratory Standards Institute.

CLSI (2007b). “Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard,” in CLSI Document M11-A7. Clinical and Laboratory Standards Institute.

Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men. Clin. Infect. Dis. 26 (1), 1–2. doi:10.1086/316284

Cuesta, I., Bieza, C., Cuenca-Estrella, M., Larrañaga, P., and Rodriguez-Tudela, J. L. (2010). Evaluation by Data Mining Techniques of Fluconazole Breakpoints Established by the Clinical and Laboratory Standards Institute (CLSI) and Comparison with Those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob. Agents Chemother. 54 (4), 1541–1546. doi:10.1128/AAC.01688-09

Cuesta, I., Bieza, C., Larrañaga, P., Cuenca-Estrella, M., Laguna, F., Rodriguez-Pardo, D., et al. (2009). Data Mining Validation of Fluconazole Breakpoints Established by the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53 (7), 2949–2954. doi:10.1128/ AAC.00081-09

Drsusano, G. L. (2004). Antimicrobial Pharmacodynamics: Critical Interactions of Drug and Drug. Nat. Rev. Microbiol. 2 (4), 289–300. doi:10.1038/nrmicro862
Huang et al. Regimens Breakpoint Avilamycin Clostridium perfringens

Gram-Negative Bacteria. *Antimicrob. Agents Chemother.* 44 (5), 1121–1126. doi:10.1128/ AAC.44.5.1121-1126.2000

Mertz, J. L., Peloso, J. S., Barker, B. J., Rabbi, G. E., Occillowitz, J. L., Simson, V. L., et al. (1986). Isolation and Structural Identification of Nine Avilamycins. *J. Antibiot. (Tokyo)* 39 (7), 877–887. doi:10.1746/antibiotics.39.877

Nan, J., Hao, H., Xie, S., Pan, Y., Xi, C., Mao, F., et al. (2017). Pharmacokinetic and Pharmacodynamic Integration and Modeling of Acetylkitasamycin in Swine for *Clostridium perfringens*. *J. Vet. Pharmacol. Ther.* 40 (Suppl. 1), 641–655. doi:10.1111/jpt.12404

OIE (2015). *OIE List of Antimicrobial Agents of Veterinary Importance Health.* Paris: World Organisation for Animal Health.

OIE (2016). *Terrestrial Animal Health Code.* World Organisation for Animal Health.

Paradis, M. A., McMillan, E., Bagg, R., Goczo, A., and Thompson, M. (2016). Efficacy of Avilamycin for the Prevention of Necrotic Enteritis Caused by a Pathogenic Strain of *Clostridium perfringens* in Broiler Chickens. *Avian Pathol.* 45 (3), 363–369. doi:10.1080/03079457.2016.1156793

Peng, Z., Hao, H., Li, J., Ijaz, A., Cheng, G., Chen, D., et al. (2016). The Epidemiologic, Pharmacodynamic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus Parasuis. *Front. Microbiol.* 7, 1085. doi:10.3389/fmicb.2016.00385

Pföller, M. A., Andrés, D., Arendrup, M. C., Diekema, J. D., Espinel-Ingroff, A., Alexander, B. D., et al. (2011). Clinical Breakpoints for Voriconazole and Candida spp. Revisited: Review of Microbiologic Molecular, Pharmacodynamic, and Clinical Data as They Pertain to the Development of Species-specific Interpretive Criteria. *Diagn. Microbiol. Infect. Dis.* 70 (3), 330–343. doi:10.1016/j.diagmicrobio.2011.03.002

Pföller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., et al. (2010). Wild-type Minimum Effective Concentration Distributions and Epidemiologic Cutoff Values for Caspofungin and Aspergillus spp. As Determined by Clinical and Laboratory Standards Institute Broth Microdilution Methods. *Diagn. Microbiol. Infect. Dis.* 67 (1), 56–60. doi:10.1016/j.diagmicrobio.2010.01.001

Ping, L., Müller, M., and Derendorf, H. (2002). Rational Dosing of Antibiotics: the Paradis, M. A., Mcmillan, E., Bagg, R., Vessie, G., Zocche, A., and Thompson, M. (2017). Pharmacokinetic and Pharmacodynamic Integration and Modeling of Acetylsarkasamycin in Swine for *Clostridium perfringens*. *J. Vet. Pharmacol. Ther.* 40 (Suppl. 1), 641–655. doi:10.1111/jpt.12404

Turnidge, J., Kahlmeter, G., and Kronvall, G. (2010). Statistical Characterisation of Bacterial Wild-type MIC Value Distributions and the Determination of Epidemiological Cut-Off Values. *Clin. Microbiol. Infect.* 12 (5), 418–425. doi:10.1111/j.1469-0691.2006.01377.x

Turnidge, J., and Paterson, D. L. (2007). Setting and Revising Antibacterial Susceptibility Breakpoints. *Clin. Microbiol. Rev.* 20 (3), 391–408. doi:10.1128/CMR.00047-06

Turnidge, J. D., and Martinez, M. N. (2017). Proposed Method for Estimating Clinical Cut-Off (COCL) Values: An Attempt to Address Challenges Encountered When Setting Clinical Breakpoints for Veterinary Antimicrobial Agents. *Vet. J.* 228, 33–37. doi:10.1016/j.tvjl.2017.10.004

VetCAST (2015). “Setting Clinical Breakpoint Methodological Aspects,” in France INRA & National Veterinary School of Toulouse. Editor P. L. Toutain.

Vissiennon, T., Kröger, H., Köhler, T., and Kliche, R. (2000). Effect of Avilamycin, Tylosin and Isonore Anticooccidials on *Clostridium perfringens* Enterotoxeraemia in Chickens. *Berl. Muench. Tierarztl. Wochenschr.* 113 (1), 9–13. doi:10.2336/139253

Waters, A. M., Avoue, A., Garmory, H. S., Bueschel, D., Popoff, M. R., Songer, J. G., et al. (2003). Genotyping and Phenotyping of Beta2-Toxigenic *Clostridium perfringens* Fecal Isolates Associated with Gastrointestinal Diseases in Piglets. *J. Clin. Microbiol.* 41 (8), 3584–3591. doi:10.1128/JCM.41.8.3584-3591.2003

Weitnauer, G., Gaisser, S., Trefzer, A., Stockert, S., Westrich, L., Quiros, L. M., et al. (2001). An ATP-Binding Cassette Transporter and Two rRNA Methytransferase Values Are Involved in Resistance to Avilamycin in the Producer Organism Streptomyces Viridochromogenes Tu57. *Antimicrob. Agents Chemother.* 45 (3), 690–695. doi:10.1128/AAC.45.3.690-695.2001

Wolf, H., Zahner, H., and Nierhaus, K. (1973). Kirromycin, an Inhibitor of the 30 S Ribosomal Subunits Function. *E.B.S. Lett.* 21 (3), 347–350. doi:10.1016/0140-7397(82)90199-6

Yadav, J. P., Das, S. C., Dhaka, P., Vijay, D., Kumar, M., Mukhopadhayay, A. K., et al. (2017). *Molecular Characterization and Antimicrobial Resistance Profile of Clostridium perfringens Type A Isolates from Humans, Animals, Fish and Their Environment. LONDON: ANAEROBE.*

Yan, L., Xie, S., Chen, D., Pan, Y., Tao, Y., Qu, W., et al. (2016). Pharmacokinetic and Pharmacodynamic Modeling of Cyadox against *Clostridium perfringens* in Swine. *Sci. Rep.* 7, 4064. doi:10.1038/s41598-017-03970-9

Yoshii, K., Ikura, M., Hirayama, M., Toda, R., and Kawabata, Y. (2016). Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcollinesterase by Acotiamide, A Novel Gastroprotective Agent for the Treatment of Functional Dyspepsia, in Rat Stomach. *Pharm. Res.* 33 (2), 292–300. doi:10.1007/s00028-015-1787-y

Zheng, X., Wang, X., Teng, D., Mao, R., Hao, Y., Yang, N., et al. (2017). Mode of Action of Plecanatin-Derived Peptides against Gas Gangrene-Associated *Clostridium perfringens* Type A. *Plos One* 12 (9), e0185215. doi:10.1371/journal.pone.0185215

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Huang, Luo, Xu, Huang, Wang, Xie, Pan, Fang, Liu, Yuan and Hao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.